nodes	percent_of_prediction	percent_of_DWPC	metapath
Asenapine—CYP1A2—Imiquimod—skin cancer	0.122	0.224	CbGbCtD
Asenapine—CYP1A2—Vemurafenib—skin cancer	0.0668	0.123	CbGbCtD
Asenapine—CYP3A4—Imiquimod—skin cancer	0.0638	0.117	CbGbCtD
Asenapine—CYP3A4—Temozolomide—skin cancer	0.0638	0.117	CbGbCtD
Asenapine—CYP2D6—Vemurafenib—skin cancer	0.055	0.101	CbGbCtD
Asenapine—CYP1A2—Dacarbazine—skin cancer	0.0512	0.0941	CbGbCtD
Asenapine—CYP3A4—Vismodegib—skin cancer	0.0443	0.0814	CbGbCtD
Asenapine—CYP3A4—Vemurafenib—skin cancer	0.035	0.0643	CbGbCtD
Asenapine—CYP1A2—Fluorouracil—skin cancer	0.03	0.0552	CbGbCtD
Asenapine—CYP3A4—Docetaxel—skin cancer	0.012	0.0221	CbGbCtD
Asenapine—HRH1—nose—skin cancer	0.00668	0.0775	CbGeAlD
Asenapine—DRD1—nerve—skin cancer	0.0041	0.0476	CbGeAlD
Asenapine—HTR5A—head—skin cancer	0.00391	0.0453	CbGeAlD
Asenapine—HTR2A—hindlimb—skin cancer	0.00263	0.0305	CbGeAlD
Asenapine—HTR1B—blood vessel—skin cancer	0.00261	0.0303	CbGeAlD
Asenapine—HTR7—nerve—skin cancer	0.00256	0.0297	CbGeAlD
Asenapine—HTR1D—blood vessel—skin cancer	0.00253	0.0293	CbGeAlD
Asenapine—DRD2—nerve—skin cancer	0.00242	0.0281	CbGeAlD
Asenapine—HTR2A—appendage—skin cancer	0.00226	0.0262	CbGeAlD
Asenapine—HTR7—endothelium—skin cancer	0.00218	0.0253	CbGeAlD
Asenapine—HTR7—blood vessel—skin cancer	0.00201	0.0234	CbGeAlD
Asenapine—HRH2—skin of body—skin cancer	0.00183	0.0213	CbGeAlD
Asenapine—Arthralgia—Vismodegib—skin cancer	0.00183	0.00676	CcSEcCtD
Asenapine—Ulcer—Dactinomycin—skin cancer	0.00181	0.0067	CcSEcCtD
Asenapine—Irritability—Imiquimod—skin cancer	0.0018	0.00663	CcSEcCtD
Asenapine—Wheezing—Bleomycin—skin cancer	0.00179	0.0066	CcSEcCtD
Asenapine—Amenorrhoea—Temozolomide—skin cancer	0.00177	0.00652	CcSEcCtD
Asenapine—Skin exfoliation—Bleomycin—skin cancer	0.00176	0.00649	CcSEcCtD
Asenapine—Nervous system disorder—Vismodegib—skin cancer	0.00172	0.00635	CcSEcCtD
Asenapine—Breast disorder—Imiquimod—skin cancer	0.0017	0.00628	CcSEcCtD
Asenapine—HTR1E—head—skin cancer	0.00167	0.0193	CbGeAlD
Asenapine—HTR2A—nerve—skin cancer	0.0016	0.0185	CbGeAlD
Asenapine—Musculoskeletal discomfort—Vismodegib—skin cancer	0.0016	0.0059	CcSEcCtD
Asenapine—Pulmonary embolism—Temozolomide—skin cancer	0.00155	0.00573	CcSEcCtD
Asenapine—Mouth ulceration—Dactinomycin—skin cancer	0.00155	0.00573	CcSEcCtD
Asenapine—Dyspepsia—Vismodegib—skin cancer	0.00154	0.0057	CcSEcCtD
Asenapine—Gastrointestinal disorder—Vismodegib—skin cancer	0.00151	0.00559	CcSEcCtD
Asenapine—Fatigue—Vismodegib—skin cancer	0.00151	0.00559	CcSEcCtD
Asenapine—Ulcer—Fluorouracil—skin cancer	0.00151	0.00558	CcSEcCtD
Asenapine—Dysarthria—Fluorouracil—skin cancer	0.00151	0.00558	CcSEcCtD
Asenapine—Oedema peripheral—Vemurafenib—skin cancer	0.0015	0.00555	CcSEcCtD
Asenapine—Constipation—Vismodegib—skin cancer	0.0015	0.00554	CcSEcCtD
Asenapine—Connective tissue disorder—Vemurafenib—skin cancer	0.0015	0.00554	CcSEcCtD
Asenapine—Skin exfoliation—Temozolomide—skin cancer	0.00148	0.00547	CcSEcCtD
Asenapine—Inflammation—Fluorouracil—skin cancer	0.00147	0.00545	CcSEcCtD
Asenapine—Depression—Imiquimod—skin cancer	0.00145	0.00534	CcSEcCtD
Asenapine—HTR7—neck—skin cancer	0.00144	0.0167	CbGeAlD
Asenapine—Eye disorder—Vemurafenib—skin cancer	0.00143	0.00526	CcSEcCtD
Asenapine—Cardiac disorder—Vemurafenib—skin cancer	0.00142	0.00523	CcSEcCtD
Asenapine—Angiopathy—Vemurafenib—skin cancer	0.00138	0.00511	CcSEcCtD
Asenapine—Mediastinal disorder—Vemurafenib—skin cancer	0.00138	0.00508	CcSEcCtD
Asenapine—Hepatobiliary disease—Imiquimod—skin cancer	0.00137	0.00506	CcSEcCtD
Asenapine—HTR2A—endothelium—skin cancer	0.00136	0.0158	CbGeAlD
Asenapine—DRD3—head—skin cancer	0.00136	0.0158	CbGeAlD
Asenapine—ADRA2C—nipple—skin cancer	0.00134	0.0155	CbGeAlD
Asenapine—Malnutrition—Vemurafenib—skin cancer	0.00133	0.0049	CcSEcCtD
Asenapine—HTR6—head—skin cancer	0.00131	0.0152	CbGeAlD
Asenapine—Dysgeusia—Vemurafenib—skin cancer	0.0013	0.0048	CcSEcCtD
Asenapine—HTR1D—connective tissue—skin cancer	0.0013	0.015	CbGeAlD
Asenapine—Connective tissue disorder—Imiquimod—skin cancer	0.00128	0.00472	CcSEcCtD
Asenapine—ADRB1—connective tissue—skin cancer	0.00126	0.0146	CbGeAlD
Asenapine—Asthenia—Vismodegib—skin cancer	0.00126	0.00465	CcSEcCtD
Asenapine—HTR2A—blood vessel—skin cancer	0.00126	0.0146	CbGeAlD
Asenapine—Eye disorder—Imiquimod—skin cancer	0.00122	0.00449	CcSEcCtD
Asenapine—HRH2—head—skin cancer	0.0012	0.0139	CbGeAlD
Asenapine—Angiopathy—Imiquimod—skin cancer	0.00118	0.00436	CcSEcCtD
Asenapine—Swelling—Fluorouracil—skin cancer	0.00118	0.00435	CcSEcCtD
Asenapine—Immune system disorder—Imiquimod—skin cancer	0.00118	0.00434	CcSEcCtD
Asenapine—Amenorrhoea—Docetaxel—skin cancer	0.00118	0.00434	CcSEcCtD
Asenapine—Mediastinal disorder—Imiquimod—skin cancer	0.00117	0.00433	CcSEcCtD
Asenapine—CYP1A2—nipple—skin cancer	0.00116	0.0135	CbGeAlD
Asenapine—Mental disorder—Imiquimod—skin cancer	0.00114	0.00421	CcSEcCtD
Asenapine—Malnutrition—Imiquimod—skin cancer	0.00113	0.00418	CcSEcCtD
Asenapine—Arthralgia—Vemurafenib—skin cancer	0.00113	0.00418	CcSEcCtD
Asenapine—Vomiting—Vismodegib—skin cancer	0.00112	0.00412	CcSEcCtD
Asenapine—Rash—Vismodegib—skin cancer	0.00111	0.00408	CcSEcCtD
Asenapine—Dermatitis—Vismodegib—skin cancer	0.00111	0.00408	CcSEcCtD
Asenapine—HTR2B—skin of body—skin cancer	0.00109	0.0126	CbGeAlD
Asenapine—HRH1—nipple—skin cancer	0.00109	0.0126	CbGeAlD
Asenapine—Dermatitis bullous—Fluorouracil—skin cancer	0.00109	0.00401	CcSEcCtD
Asenapine—Anaphylactic shock—Vemurafenib—skin cancer	0.00108	0.004	CcSEcCtD
Asenapine—Dysphagia—Dactinomycin—skin cancer	0.00108	0.00398	CcSEcCtD
Asenapine—ADRA2A—nipple—skin cancer	0.00107	0.0124	CbGeAlD
Asenapine—Inflammation—Docetaxel—skin cancer	0.00106	0.00393	CcSEcCtD
Asenapine—Nervous system disorder—Vemurafenib—skin cancer	0.00106	0.00393	CcSEcCtD
Asenapine—Nausea—Vismodegib—skin cancer	0.00104	0.00385	CcSEcCtD
Asenapine—Agitation—Imiquimod—skin cancer	0.00104	0.00384	CcSEcCtD
Asenapine—Osteoarthritis—Fluorouracil—skin cancer	0.00104	0.00383	CcSEcCtD
Asenapine—Angioedema—Imiquimod—skin cancer	0.00103	0.00382	CcSEcCtD
Asenapine—Pulmonary embolism—Docetaxel—skin cancer	0.00103	0.00381	CcSEcCtD
Asenapine—HTR7—connective tissue—skin cancer	0.00103	0.012	CbGeAlD
Asenapine—Malaise—Imiquimod—skin cancer	0.00102	0.00377	CcSEcCtD
Asenapine—Breast disorder—Temozolomide—skin cancer	0.00102	0.00376	CcSEcCtD
Asenapine—Syncope—Imiquimod—skin cancer	0.00102	0.00375	CcSEcCtD
Asenapine—Hypotension—Vemurafenib—skin cancer	0.00101	0.00374	CcSEcCtD
Asenapine—Neutropenia—Dactinomycin—skin cancer	0.00101	0.00372	CcSEcCtD
Asenapine—Stomatitis—Bleomycin—skin cancer	0.001	0.00371	CcSEcCtD
Asenapine—Loss of consciousness—Imiquimod—skin cancer	0.000995	0.00368	CcSEcCtD
Asenapine—Alanine aminotransferase increased—Temozolomide—skin cancer	0.000994	0.00367	CcSEcCtD
Asenapine—Irritability—Fluorouracil—skin cancer	0.000991	0.00366	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.000988	0.00365	CcSEcCtD
Asenapine—Skin exfoliation—Docetaxel—skin cancer	0.000986	0.00364	CcSEcCtD
Asenapine—Convulsion—Imiquimod—skin cancer	0.000981	0.00362	CcSEcCtD
Asenapine—HTR7—epithelium—skin cancer	0.00098	0.0114	CbGeAlD
Asenapine—Hypertension—Imiquimod—skin cancer	0.000978	0.00361	CcSEcCtD
Asenapine—Dysphagia—Temozolomide—skin cancer	0.000974	0.0036	CcSEcCtD
Asenapine—DRD1—head—skin cancer	0.000973	0.0113	CbGeAlD
Asenapine—Arthralgia—Imiquimod—skin cancer	0.000964	0.00356	CcSEcCtD
Asenapine—Anxiety—Imiquimod—skin cancer	0.000961	0.00355	CcSEcCtD
Asenapine—ADRA1A—epithelium—skin cancer	0.000945	0.011	CbGeAlD
Asenapine—HTR1B—female reproductive system—skin cancer	0.000944	0.011	CbGeAlD
Asenapine—Dry mouth—Imiquimod—skin cancer	0.000943	0.00348	CcSEcCtD
Asenapine—Stomatitis—Dactinomycin—skin cancer	0.000936	0.00346	CcSEcCtD
Asenapine—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000936	0.00346	CcSEcCtD
Asenapine—Fatigue—Vemurafenib—skin cancer	0.000935	0.00345	CcSEcCtD
Asenapine—Constipation—Vemurafenib—skin cancer	0.000927	0.00342	CcSEcCtD
Asenapine—HTR1D—female reproductive system—skin cancer	0.000914	0.0106	CbGeAlD
Asenapine—Neutropenia—Temozolomide—skin cancer	0.000911	0.00336	CcSEcCtD
Asenapine—Shock—Imiquimod—skin cancer	0.000909	0.00336	CcSEcCtD
Asenapine—Nervous system disorder—Imiquimod—skin cancer	0.000907	0.00335	CcSEcCtD
Asenapine—HTR2C—female reproductive system—skin cancer	0.000905	0.0105	CbGeAlD
Asenapine—Tachycardia—Imiquimod—skin cancer	0.000902	0.00333	CcSEcCtD
Asenapine—HTR2A—neck—skin cancer	0.000898	0.0104	CbGeAlD
Asenapine—Dysphagia—Fluorouracil—skin cancer	0.000898	0.00331	CcSEcCtD
Asenapine—Agranulocytosis—Dactinomycin—skin cancer	0.000896	0.00331	CcSEcCtD
Asenapine—ADRB1—female reproductive system—skin cancer	0.000888	0.0103	CbGeAlD
Asenapine—Weight increased—Temozolomide—skin cancer	0.000887	0.00327	CcSEcCtD
Asenapine—Hyperglycaemia—Temozolomide—skin cancer	0.000879	0.00324	CcSEcCtD
Asenapine—Depression—Temozolomide—skin cancer	0.000866	0.0032	CcSEcCtD
Asenapine—SLC6A4—female reproductive system—skin cancer	0.000858	0.00995	CbGeAlD
Asenapine—HTR2B—female reproductive system—skin cancer	0.00085	0.00986	CbGeAlD
Asenapine—Swelling—Docetaxel—skin cancer	0.00085	0.00314	CcSEcCtD
Asenapine—Stomatitis—Temozolomide—skin cancer	0.000847	0.00313	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000842	0.00311	CcSEcCtD
Asenapine—HRH2—lymph node—skin cancer	0.000838	0.00972	CbGeAlD
Asenapine—Insomnia—Imiquimod—skin cancer	0.000836	0.00309	CcSEcCtD
Asenapine—Dyspnoea—Imiquimod—skin cancer	0.000824	0.00304	CcSEcCtD
Asenapine—Somnolence—Imiquimod—skin cancer	0.000822	0.00303	CcSEcCtD
Asenapine—Hepatobiliary disease—Temozolomide—skin cancer	0.000821	0.00303	CcSEcCtD
Asenapine—Dyspepsia—Imiquimod—skin cancer	0.000814	0.003	CcSEcCtD
Asenapine—Hypersensitivity—Vemurafenib—skin cancer	0.000799	0.00295	CcSEcCtD
Asenapine—Gastrointestinal disorder—Imiquimod—skin cancer	0.000798	0.00295	CcSEcCtD
Asenapine—Fatigue—Imiquimod—skin cancer	0.000797	0.00294	CcSEcCtD
Asenapine—HTR1B—head—skin cancer	0.000789	0.00915	CbGeAlD
Asenapine—Dermatitis bullous—Docetaxel—skin cancer	0.000784	0.0029	CcSEcCtD
Asenapine—ADRA2C—mammalian vulva—skin cancer	0.000781	0.00906	CbGeAlD
Asenapine—Stomatitis—Fluorouracil—skin cancer	0.00078	0.00288	CcSEcCtD
Asenapine—Asthenia—Vemurafenib—skin cancer	0.000778	0.00287	CcSEcCtD
Asenapine—HRH1—connective tissue—skin cancer	0.000771	0.00894	CbGeAlD
Asenapine—Oedema peripheral—Temozolomide—skin cancer	0.000768	0.00284	CcSEcCtD
Asenapine—Connective tissue disorder—Temozolomide—skin cancer	0.000766	0.00283	CcSEcCtD
Asenapine—HTR1D—head—skin cancer	0.000763	0.00886	CbGeAlD
Asenapine—ADRA2A—connective tissue—skin cancer	0.000757	0.00878	CbGeAlD
Asenapine—HTR2C—head—skin cancer	0.000756	0.00877	CbGeAlD
Asenapine—Hyponatraemia—Docetaxel—skin cancer	0.000753	0.00278	CcSEcCtD
Asenapine—Pain in extremity—Docetaxel—skin cancer	0.00075	0.00277	CcSEcCtD
Asenapine—Agranulocytosis—Fluorouracil—skin cancer	0.000747	0.00276	CcSEcCtD
Asenapine—Anaemia—Bleomycin—skin cancer	0.000744	0.00275	CcSEcCtD
Asenapine—ADRB1—head—skin cancer	0.000742	0.00861	CbGeAlD
Asenapine—HRH1—epithelium—skin cancer	0.000732	0.00849	CbGeAlD
Asenapine—Eye disorder—Temozolomide—skin cancer	0.000729	0.00269	CcSEcCtD
Asenapine—ADRA1A—lymphoid tissue—skin cancer	0.000728	0.00845	CbGeAlD
Asenapine—HTR7—female reproductive system—skin cancer	0.000728	0.00845	CbGeAlD
Asenapine—Malaise—Bleomycin—skin cancer	0.000726	0.00268	CcSEcCtD
Asenapine—Cardiac disorder—Temozolomide—skin cancer	0.000724	0.00267	CcSEcCtD
Asenapine—Leukopenia—Bleomycin—skin cancer	0.00072	0.00266	CcSEcCtD
Asenapine—Dizziness—Vemurafenib—skin cancer	0.000717	0.00265	CcSEcCtD
Asenapine—SLC6A4—head—skin cancer	0.000717	0.00832	CbGeAlD
Asenapine—HTR2B—head—skin cancer	0.00071	0.00824	CbGeAlD
Asenapine—Angiopathy—Temozolomide—skin cancer	0.000707	0.00261	CcSEcCtD
Asenapine—Immune system disorder—Temozolomide—skin cancer	0.000704	0.0026	CcSEcCtD
Asenapine—Mediastinal disorder—Temozolomide—skin cancer	0.000703	0.00259	CcSEcCtD
Asenapine—Anaemia—Dactinomycin—skin cancer	0.000694	0.00256	CcSEcCtD
Asenapine—Vomiting—Vemurafenib—skin cancer	0.000689	0.00254	CcSEcCtD
Asenapine—Orthostatic hypotension—Docetaxel—skin cancer	0.000685	0.00253	CcSEcCtD
Asenapine—Rash—Vemurafenib—skin cancer	0.000683	0.00252	CcSEcCtD
Asenapine—Mental disorder—Temozolomide—skin cancer	0.000683	0.00252	CcSEcCtD
Asenapine—Dermatitis—Vemurafenib—skin cancer	0.000683	0.00252	CcSEcCtD
Asenapine—Hypersensitivity—Imiquimod—skin cancer	0.000681	0.00251	CcSEcCtD
Asenapine—Headache—Vemurafenib—skin cancer	0.000679	0.00251	CcSEcCtD
Asenapine—Malnutrition—Temozolomide—skin cancer	0.000679	0.00251	CcSEcCtD
Asenapine—Breast disorder—Docetaxel—skin cancer	0.000677	0.0025	CcSEcCtD
Asenapine—Malaise—Dactinomycin—skin cancer	0.000677	0.0025	CcSEcCtD
Asenapine—Leukopenia—Dactinomycin—skin cancer	0.000672	0.00248	CcSEcCtD
Asenapine—Dysgeusia—Temozolomide—skin cancer	0.000665	0.00245	CcSEcCtD
Asenapine—Asthenia—Imiquimod—skin cancer	0.000663	0.00245	CcSEcCtD
Asenapine—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000661	0.00244	CcSEcCtD
Asenapine—Anaphylactic shock—Bleomycin—skin cancer	0.000657	0.00242	CcSEcCtD
Asenapine—Dysphagia—Docetaxel—skin cancer	0.000648	0.00239	CcSEcCtD
Asenapine—Nausea—Vemurafenib—skin cancer	0.000644	0.00238	CcSEcCtD
Asenapine—HTR2A—connective tissue—skin cancer	0.000644	0.00747	CbGeAlD
Asenapine—Thrombocytopenia—Bleomycin—skin cancer	0.000643	0.00237	CcSEcCtD
Asenapine—HTR1A—head—skin cancer	0.000636	0.00738	CbGeAlD
Asenapine—Tremor—Temozolomide—skin cancer	0.000636	0.00235	CcSEcCtD
Asenapine—HRH1—mammalian vulva—skin cancer	0.000635	0.00736	CbGeAlD
Asenapine—Anaemia—Temozolomide—skin cancer	0.000627	0.00232	CcSEcCtD
Asenapine—Agitation—Temozolomide—skin cancer	0.000624	0.0023	CcSEcCtD
Asenapine—ADRA2A—mammalian vulva—skin cancer	0.000623	0.00723	CbGeAlD
Asenapine—Angioedema—Temozolomide—skin cancer	0.00062	0.00229	CcSEcCtD
Asenapine—Hypotension—Bleomycin—skin cancer	0.000614	0.00227	CcSEcCtD
Asenapine—Malaise—Temozolomide—skin cancer	0.000612	0.00226	CcSEcCtD
Asenapine—Dizziness—Imiquimod—skin cancer	0.000611	0.00226	CcSEcCtD
Asenapine—HTR2A—epithelium—skin cancer	0.000611	0.00709	CbGeAlD
Asenapine—HTR7—head—skin cancer	0.000608	0.00706	CbGeAlD
Asenapine—Leukopenia—Temozolomide—skin cancer	0.000608	0.00224	CcSEcCtD
Asenapine—Neutropenia—Docetaxel—skin cancer	0.000606	0.00224	CcSEcCtD
Asenapine—Thrombocytopenia—Dactinomycin—skin cancer	0.0006	0.00221	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000598	0.00221	CcSEcCtD
Asenapine—Weight increased—Docetaxel—skin cancer	0.00059	0.00218	CcSEcCtD
Asenapine—Convulsion—Temozolomide—skin cancer	0.000588	0.00217	CcSEcCtD
Asenapine—Vomiting—Imiquimod—skin cancer	0.000588	0.00217	CcSEcCtD
Asenapine—ADRA1A—head—skin cancer	0.000587	0.00681	CbGeAlD
Asenapine—Hypertension—Temozolomide—skin cancer	0.000586	0.00216	CcSEcCtD
Asenapine—Dyspnoea—Bleomycin—skin cancer	0.000585	0.00216	CcSEcCtD
Asenapine—Rash—Imiquimod—skin cancer	0.000583	0.00215	CcSEcCtD
Asenapine—Dermatitis—Imiquimod—skin cancer	0.000582	0.00215	CcSEcCtD
Asenapine—Headache—Imiquimod—skin cancer	0.000579	0.00214	CcSEcCtD
Asenapine—Anaemia—Fluorouracil—skin cancer	0.000578	0.00213	CcSEcCtD
Asenapine—Arthralgia—Temozolomide—skin cancer	0.000578	0.00213	CcSEcCtD
Asenapine—Anxiety—Temozolomide—skin cancer	0.000576	0.00213	CcSEcCtD
Asenapine—DRD2—head—skin cancer	0.000575	0.00667	CbGeAlD
Asenapine—Dry mouth—Temozolomide—skin cancer	0.000565	0.00209	CcSEcCtD
Asenapine—Stomatitis—Docetaxel—skin cancer	0.000563	0.00208	CcSEcCtD
Asenapine—Leukopenia—Fluorouracil—skin cancer	0.00056	0.00207	CcSEcCtD
Asenapine—ADRA2C—head—skin cancer	0.000559	0.00649	CbGeAlD
Asenapine—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000558	0.00206	CcSEcCtD
Asenapine—Anaphylactic shock—Temozolomide—skin cancer	0.000554	0.00205	CcSEcCtD
Asenapine—Nausea—Imiquimod—skin cancer	0.000549	0.00203	CcSEcCtD
Asenapine—Hepatobiliary disease—Docetaxel—skin cancer	0.000546	0.00202	CcSEcCtD
Asenapine—HRH1—female reproductive system—skin cancer	0.000544	0.00631	CbGeAlD
Asenapine—Nervous system disorder—Temozolomide—skin cancer	0.000543	0.00201	CcSEcCtD
Asenapine—Thrombocytopenia—Temozolomide—skin cancer	0.000542	0.002	CcSEcCtD
Asenapine—Convulsion—Fluorouracil—skin cancer	0.000542	0.002	CcSEcCtD
Asenapine—Agranulocytosis—Docetaxel—skin cancer	0.000539	0.00199	CcSEcCtD
Asenapine—ADRA2A—female reproductive system—skin cancer	0.000534	0.00619	CbGeAlD
Asenapine—Fatigue—Dactinomycin—skin cancer	0.000528	0.00195	CcSEcCtD
Asenapine—Oedema peripheral—Docetaxel—skin cancer	0.000511	0.00189	CcSEcCtD
Asenapine—Anaphylactic shock—Fluorouracil—skin cancer	0.00051	0.00188	CcSEcCtD
Asenapine—Connective tissue disorder—Docetaxel—skin cancer	0.00051	0.00188	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000505	0.00186	CcSEcCtD
Asenapine—Insomnia—Temozolomide—skin cancer	0.000501	0.00185	CcSEcCtD
Asenapine—Nervous system disorder—Fluorouracil—skin cancer	0.000501	0.00185	CcSEcCtD
Asenapine—Thrombocytopenia—Fluorouracil—skin cancer	0.0005	0.00185	CcSEcCtD
Asenapine—Tachycardia—Fluorouracil—skin cancer	0.000498	0.00184	CcSEcCtD
Asenapine—HTR2B—lymph node—skin cancer	0.000497	0.00577	CbGeAlD
Asenapine—Dyspnoea—Temozolomide—skin cancer	0.000494	0.00182	CcSEcCtD
Asenapine—Somnolence—Temozolomide—skin cancer	0.000492	0.00182	CcSEcCtD
Asenapine—Dyspepsia—Temozolomide—skin cancer	0.000488	0.0018	CcSEcCtD
Asenapine—Eye disorder—Docetaxel—skin cancer	0.000485	0.00179	CcSEcCtD
Asenapine—Hypersensitivity—Bleomycin—skin cancer	0.000484	0.00179	CcSEcCtD
Asenapine—Cardiac disorder—Docetaxel—skin cancer	0.000481	0.00178	CcSEcCtD
Asenapine—Gastrointestinal disorder—Temozolomide—skin cancer	0.000478	0.00177	CcSEcCtD
Asenapine—Fatigue—Temozolomide—skin cancer	0.000478	0.00176	CcSEcCtD
Asenapine—Hypotension—Fluorouracil—skin cancer	0.000477	0.00176	CcSEcCtD
Asenapine—Constipation—Temozolomide—skin cancer	0.000474	0.00175	CcSEcCtD
Asenapine—Asthenia—Bleomycin—skin cancer	0.000471	0.00174	CcSEcCtD
Asenapine—Angiopathy—Docetaxel—skin cancer	0.00047	0.00174	CcSEcCtD
Asenapine—Immune system disorder—Docetaxel—skin cancer	0.000468	0.00173	CcSEcCtD
Asenapine—Mediastinal disorder—Docetaxel—skin cancer	0.000467	0.00173	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000465	0.00172	CcSEcCtD
Asenapine—Insomnia—Fluorouracil—skin cancer	0.000462	0.0017	CcSEcCtD
Asenapine—Dyspnoea—Fluorouracil—skin cancer	0.000455	0.00168	CcSEcCtD
Asenapine—Mental disorder—Docetaxel—skin cancer	0.000454	0.00168	CcSEcCtD
Asenapine—HRH1—head—skin cancer	0.000454	0.00527	CbGeAlD
Asenapine—HTR2A—female reproductive system—skin cancer	0.000454	0.00527	CbGeAlD
Asenapine—Somnolence—Fluorouracil—skin cancer	0.000454	0.00168	CcSEcCtD
Asenapine—Malnutrition—Docetaxel—skin cancer	0.000451	0.00167	CcSEcCtD
Asenapine—Hypersensitivity—Dactinomycin—skin cancer	0.000451	0.00167	CcSEcCtD
Asenapine—Dyspepsia—Fluorouracil—skin cancer	0.000449	0.00166	CcSEcCtD
Asenapine—ADRA2A—head—skin cancer	0.000446	0.00517	CbGeAlD
Asenapine—Dysgeusia—Docetaxel—skin cancer	0.000442	0.00163	CcSEcCtD
Asenapine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000441	0.00163	CcSEcCtD
Asenapine—Asthenia—Dactinomycin—skin cancer	0.000439	0.00162	CcSEcCtD
Asenapine—Muscle spasms—Docetaxel—skin cancer	0.000434	0.0016	CcSEcCtD
Asenapine—CYP3A4—female reproductive system—skin cancer	0.00042	0.00488	CbGeAlD
Asenapine—Vomiting—Bleomycin—skin cancer	0.000418	0.00154	CcSEcCtD
Asenapine—Anaemia—Docetaxel—skin cancer	0.000417	0.00154	CcSEcCtD
Asenapine—Rash—Bleomycin—skin cancer	0.000414	0.00153	CcSEcCtD
Asenapine—Dermatitis—Bleomycin—skin cancer	0.000414	0.00153	CcSEcCtD
Asenapine—CYP2D6—female reproductive system—skin cancer	0.000414	0.0048	CbGeAlD
Asenapine—Hypersensitivity—Temozolomide—skin cancer	0.000408	0.00151	CcSEcCtD
Asenapine—Syncope—Docetaxel—skin cancer	0.000405	0.00149	CcSEcCtD
Asenapine—Leukopenia—Docetaxel—skin cancer	0.000404	0.00149	CcSEcCtD
Asenapine—Asthenia—Temozolomide—skin cancer	0.000397	0.00147	CcSEcCtD
Asenapine—Loss of consciousness—Docetaxel—skin cancer	0.000397	0.00146	CcSEcCtD
Asenapine—ADRA2C—lymph node—skin cancer	0.000391	0.00454	CbGeAlD
Asenapine—Convulsion—Docetaxel—skin cancer	0.000391	0.00144	CcSEcCtD
Asenapine—Nausea—Bleomycin—skin cancer	0.00039	0.00144	CcSEcCtD
Asenapine—Hypertension—Docetaxel—skin cancer	0.00039	0.00144	CcSEcCtD
Asenapine—Vomiting—Dactinomycin—skin cancer	0.000389	0.00144	CcSEcCtD
Asenapine—Rash—Dactinomycin—skin cancer	0.000386	0.00143	CcSEcCtD
Asenapine—Arthralgia—Docetaxel—skin cancer	0.000384	0.00142	CcSEcCtD
Asenapine—HTR2A—head—skin cancer	0.000379	0.0044	CbGeAlD
Asenapine—Hypersensitivity—Fluorouracil—skin cancer	0.000376	0.00139	CcSEcCtD
Asenapine—Dry mouth—Docetaxel—skin cancer	0.000376	0.00139	CcSEcCtD
Asenapine—Anaphylactic shock—Docetaxel—skin cancer	0.000368	0.00136	CcSEcCtD
Asenapine—Dizziness—Temozolomide—skin cancer	0.000366	0.00135	CcSEcCtD
Asenapine—Nausea—Dactinomycin—skin cancer	0.000364	0.00134	CcSEcCtD
Asenapine—Shock—Docetaxel—skin cancer	0.000362	0.00134	CcSEcCtD
Asenapine—Nervous system disorder—Docetaxel—skin cancer	0.000361	0.00133	CcSEcCtD
Asenapine—Thrombocytopenia—Docetaxel—skin cancer	0.000361	0.00133	CcSEcCtD
Asenapine—Tachycardia—Docetaxel—skin cancer	0.00036	0.00133	CcSEcCtD
Asenapine—Vomiting—Temozolomide—skin cancer	0.000352	0.0013	CcSEcCtD
Asenapine—Rash—Temozolomide—skin cancer	0.000349	0.00129	CcSEcCtD
Asenapine—Dermatitis—Temozolomide—skin cancer	0.000349	0.00129	CcSEcCtD
Asenapine—Headache—Temozolomide—skin cancer	0.000347	0.00128	CcSEcCtD
Asenapine—CYP2D6—head—skin cancer	0.000345	0.00401	CbGeAlD
Asenapine—Hypotension—Docetaxel—skin cancer	0.000344	0.00127	CcSEcCtD
Asenapine—Dizziness—Fluorouracil—skin cancer	0.000338	0.00125	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000336	0.00124	CcSEcCtD
Asenapine—Insomnia—Docetaxel—skin cancer	0.000333	0.00123	CcSEcCtD
Asenapine—Nausea—Temozolomide—skin cancer	0.000329	0.00121	CcSEcCtD
Asenapine—Dyspnoea—Docetaxel—skin cancer	0.000328	0.00121	CcSEcCtD
Asenapine—Somnolence—Docetaxel—skin cancer	0.000328	0.00121	CcSEcCtD
Asenapine—Vomiting—Fluorouracil—skin cancer	0.000325	0.0012	CcSEcCtD
Asenapine—Dyspepsia—Docetaxel—skin cancer	0.000324	0.0012	CcSEcCtD
Asenapine—Rash—Fluorouracil—skin cancer	0.000322	0.00119	CcSEcCtD
Asenapine—Dermatitis—Fluorouracil—skin cancer	0.000322	0.00119	CcSEcCtD
Asenapine—Headache—Fluorouracil—skin cancer	0.00032	0.00118	CcSEcCtD
Asenapine—Gastrointestinal disorder—Docetaxel—skin cancer	0.000318	0.00117	CcSEcCtD
Asenapine—HRH1—lymph node—skin cancer	0.000318	0.00369	CbGeAlD
Asenapine—Fatigue—Docetaxel—skin cancer	0.000318	0.00117	CcSEcCtD
Asenapine—Constipation—Docetaxel—skin cancer	0.000315	0.00116	CcSEcCtD
Asenapine—ADRA2A—lymph node—skin cancer	0.000312	0.00362	CbGeAlD
Asenapine—Nausea—Fluorouracil—skin cancer	0.000303	0.00112	CcSEcCtD
Asenapine—Hypersensitivity—Docetaxel—skin cancer	0.000271	0.001	CcSEcCtD
Asenapine—Asthenia—Docetaxel—skin cancer	0.000264	0.000976	CcSEcCtD
Asenapine—Dizziness—Docetaxel—skin cancer	0.000244	0.0009	CcSEcCtD
Asenapine—Vomiting—Docetaxel—skin cancer	0.000234	0.000865	CcSEcCtD
Asenapine—Rash—Docetaxel—skin cancer	0.000232	0.000858	CcSEcCtD
Asenapine—Dermatitis—Docetaxel—skin cancer	0.000232	0.000857	CcSEcCtD
Asenapine—Headache—Docetaxel—skin cancer	0.000231	0.000852	CcSEcCtD
Asenapine—Nausea—Docetaxel—skin cancer	0.000219	0.000808	CcSEcCtD
Asenapine—ADRA2B—Hemostasis—KRAS—skin cancer	2.37e-05	0.000239	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—FOXO4—skin cancer	2.34e-05	0.000236	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—TERT—skin cancer	2.34e-05	0.000236	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—FOXO4—skin cancer	2.34e-05	0.000236	CbGpPWpGaD
Asenapine—HRH2—Signaling by GPCR—KRAS—skin cancer	2.31e-05	0.000233	CbGpPWpGaD
Asenapine—HTR5A—Signaling Pathways—IL6—skin cancer	2.31e-05	0.000233	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—FOXO4—skin cancer	2.3e-05	0.000231	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—ERCC2—skin cancer	2.24e-05	0.000226	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—TERT—skin cancer	2.23e-05	0.000225	CbGpPWpGaD
Asenapine—ADRA2C—Hemostasis—KRAS—skin cancer	2.22e-05	0.000223	CbGpPWpGaD
Asenapine—HTR1E—Signaling by GPCR—HRAS—skin cancer	2.21e-05	0.000223	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—FOXO4—skin cancer	2.13e-05	0.000215	CbGpPWpGaD
Asenapine—HTR1E—Signaling by GPCR—IL6—skin cancer	2.11e-05	0.000213	CbGpPWpGaD
Asenapine—ADRA2B—Hemostasis—TP53—skin cancer	2.11e-05	0.000213	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—TERT—skin cancer	2.11e-05	0.000212	CbGpPWpGaD
Asenapine—ADRA2A—Hemostasis—NRAS—skin cancer	2.09e-05	0.000211	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—TERT—skin cancer	2.08e-05	0.00021	CbGpPWpGaD
Asenapine—HTR6—Signaling by GPCR—NRAS—skin cancer	2.06e-05	0.000208	CbGpPWpGaD
Asenapine—HTR7—Signaling by GPCR—NRAS—skin cancer	2.06e-05	0.000208	CbGpPWpGaD
Asenapine—HTR1D—Signaling by GPCR—NRAS—skin cancer	2.05e-05	0.000206	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—ENO2—skin cancer	2.04e-05	0.000206	CbGpPWpGaD
Asenapine—ADRA2B—Hemostasis—HRAS—skin cancer	2.02e-05	0.000203	CbGpPWpGaD
Asenapine—HTR1B—Signaling by GPCR—NRAS—skin cancer	2e-05	0.000202	CbGpPWpGaD
Asenapine—DRD4—Signaling by GPCR—NRAS—skin cancer	1.97e-05	0.000199	CbGpPWpGaD
Asenapine—ADRA2C—Hemostasis—TP53—skin cancer	1.97e-05	0.000199	CbGpPWpGaD
Asenapine—HRH2—Signaling by GPCR—HRAS—skin cancer	1.97e-05	0.000198	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—CSPG4—skin cancer	1.96e-05	0.000198	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—BRAF—skin cancer	1.94e-05	0.000195	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—BRAF—skin cancer	1.94e-05	0.000195	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—BRAF—skin cancer	1.92e-05	0.000194	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—TERT—skin cancer	1.89e-05	0.000191	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—BRAF—skin cancer	1.88e-05	0.00019	CbGpPWpGaD
Asenapine—ADRA2C—Hemostasis—HRAS—skin cancer	1.88e-05	0.00019	CbGpPWpGaD
Asenapine—HRH2—Signaling by GPCR—IL6—skin cancer	1.88e-05	0.00019	CbGpPWpGaD
Asenapine—HTR2B—Signaling by GPCR—NRAS—skin cancer	1.88e-05	0.00019	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—TERT—skin cancer	1.88e-05	0.000189	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—BRAF—skin cancer	1.85e-05	0.000187	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—TERT—skin cancer	1.85e-05	0.000187	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—ERCC2—skin cancer	1.82e-05	0.000183	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—TERT—skin cancer	1.81e-05	0.000183	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—TERT—skin cancer	1.8e-05	0.000182	CbGpPWpGaD
Asenapine—ADRA2A—Hemostasis—KRAS—skin cancer	1.8e-05	0.000181	CbGpPWpGaD
Asenapine—HTR1E—Signaling Pathways—NRAS—skin cancer	1.78e-05	0.00018	CbGpPWpGaD
Asenapine—DRD1—Signaling by GPCR—NRAS—skin cancer	1.78e-05	0.000179	CbGpPWpGaD
Asenapine—HTR6—Signaling by GPCR—KRAS—skin cancer	1.78e-05	0.000179	CbGpPWpGaD
Asenapine—HTR7—Signaling by GPCR—KRAS—skin cancer	1.77e-05	0.000179	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—BRAF—skin cancer	1.77e-05	0.000178	CbGpPWpGaD
Asenapine—HTR1D—Signaling by GPCR—KRAS—skin cancer	1.76e-05	0.000178	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—TERT—skin cancer	1.75e-05	0.000177	CbGpPWpGaD
Asenapine—DRD3—Signaling by GPCR—NRAS—skin cancer	1.75e-05	0.000177	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—ENO2—skin cancer	1.73e-05	0.000174	CbGpPWpGaD
Asenapine—HTR1B—Signaling by GPCR—KRAS—skin cancer	1.72e-05	0.000174	CbGpPWpGaD
Asenapine—DRD4—Signaling by GPCR—KRAS—skin cancer	1.7e-05	0.000171	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—BRAF—skin cancer	1.67e-05	0.000168	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—BRAF—skin cancer	1.65e-05	0.000166	CbGpPWpGaD
Asenapine—HTR2B—Signaling by GPCR—KRAS—skin cancer	1.62e-05	0.000163	CbGpPWpGaD
Asenapine—ADRA2A—Hemostasis—TP53—skin cancer	1.6e-05	0.000161	CbGpPWpGaD
Asenapine—ADRB1—Signaling by GPCR—NRAS—skin cancer	1.6e-05	0.000161	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—TERT—skin cancer	1.59e-05	0.00016	CbGpPWpGaD
Asenapine—HRH2—Signaling Pathways—NRAS—skin cancer	1.59e-05	0.00016	CbGpPWpGaD
Asenapine—ADRA2B—Signaling by GPCR—NRAS—skin cancer	1.58e-05	0.000159	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—TERT—skin cancer	1.57e-05	0.000158	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—TERT—skin cancer	1.56e-05	0.000158	CbGpPWpGaD
Asenapine—ADRB2—Signaling by GPCR—NRAS—skin cancer	1.56e-05	0.000157	CbGpPWpGaD
Asenapine—HTR1E—Signaling Pathways—KRAS—skin cancer	1.54e-05	0.000155	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—TERT—skin cancer	1.53e-05	0.000155	CbGpPWpGaD
Asenapine—ADRA2A—Hemostasis—HRAS—skin cancer	1.53e-05	0.000154	CbGpPWpGaD
Asenapine—DRD1—Signaling by GPCR—KRAS—skin cancer	1.53e-05	0.000154	CbGpPWpGaD
Asenapine—HTR1A—Signaling by GPCR—NRAS—skin cancer	1.53e-05	0.000154	CbGpPWpGaD
Asenapine—HTR2C—Signaling by GPCR—NRAS—skin cancer	1.52e-05	0.000153	CbGpPWpGaD
Asenapine—HTR6—Signaling by GPCR—HRAS—skin cancer	1.51e-05	0.000152	CbGpPWpGaD
Asenapine—DRD3—Signaling by GPCR—KRAS—skin cancer	1.51e-05	0.000152	CbGpPWpGaD
Asenapine—HTR7—Signaling by GPCR—HRAS—skin cancer	1.51e-05	0.000152	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—BRAF—skin cancer	1.5e-05	0.000151	CbGpPWpGaD
Asenapine—HTR1D—Signaling by GPCR—HRAS—skin cancer	1.5e-05	0.000151	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—BRAF—skin cancer	1.49e-05	0.00015	CbGpPWpGaD
Asenapine—ADRA2C—Signaling by GPCR—NRAS—skin cancer	1.48e-05	0.000149	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—BRAF—skin cancer	1.47e-05	0.000148	CbGpPWpGaD
Asenapine—HTR1B—Signaling by GPCR—HRAS—skin cancer	1.47e-05	0.000148	CbGpPWpGaD
Asenapine—HTR6—Signaling by GPCR—IL6—skin cancer	1.44e-05	0.000146	CbGpPWpGaD
Asenapine—DRD4—Signaling by GPCR—HRAS—skin cancer	1.44e-05	0.000145	CbGpPWpGaD
Asenapine—HTR7—Signaling by GPCR—IL6—skin cancer	1.44e-05	0.000145	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—BRAF—skin cancer	1.44e-05	0.000145	CbGpPWpGaD
Asenapine—HTR1D—Signaling by GPCR—IL6—skin cancer	1.43e-05	0.000145	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—BRAF—skin cancer	1.43e-05	0.000144	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—TERT—skin cancer	1.42e-05	0.000144	CbGpPWpGaD
Asenapine—HTR1B—Signaling by GPCR—IL6—skin cancer	1.4e-05	0.000142	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—BRAF—skin cancer	1.39e-05	0.00014	CbGpPWpGaD
Asenapine—DRD4—Signaling by GPCR—IL6—skin cancer	1.38e-05	0.000139	CbGpPWpGaD
Asenapine—HTR2B—Signaling by GPCR—HRAS—skin cancer	1.38e-05	0.000139	CbGpPWpGaD
Asenapine—ADRB1—Signaling by GPCR—KRAS—skin cancer	1.37e-05	0.000139	CbGpPWpGaD
Asenapine—HRH2—Signaling Pathways—KRAS—skin cancer	1.37e-05	0.000138	CbGpPWpGaD
Asenapine—HTR1E—Signaling Pathways—TP53—skin cancer	1.36e-05	0.000138	CbGpPWpGaD
Asenapine—ADRA2B—Signaling by GPCR—KRAS—skin cancer	1.36e-05	0.000137	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.35e-05	0.000136	CbGpPWpGaD
Asenapine—ADRB2—Signaling by GPCR—KRAS—skin cancer	1.34e-05	0.000136	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—PTGS2—skin cancer	1.34e-05	0.000135	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—NRAS—skin cancer	1.34e-05	0.000135	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—ENO2—skin cancer	1.33e-05	0.000134	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—NRAS—skin cancer	1.32e-05	0.000133	CbGpPWpGaD
Asenapine—HTR2B—Signaling by GPCR—IL6—skin cancer	1.32e-05	0.000133	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—NRAS—skin cancer	1.32e-05	0.000133	CbGpPWpGaD
Asenapine—HTR1A—Signaling by GPCR—KRAS—skin cancer	1.31e-05	0.000132	CbGpPWpGaD
Asenapine—HTR2C—Signaling by GPCR—KRAS—skin cancer	1.31e-05	0.000132	CbGpPWpGaD
Asenapine—HTR1E—Signaling Pathways—HRAS—skin cancer	1.3e-05	0.000132	CbGpPWpGaD
Asenapine—DRD1—Signaling by GPCR—HRAS—skin cancer	1.3e-05	0.000131	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—NRAS—skin cancer	1.29e-05	0.00013	CbGpPWpGaD
Asenapine—DRD3—Signaling by GPCR—HRAS—skin cancer	1.28e-05	0.000129	CbGpPWpGaD
Asenapine—ADRA2C—Signaling by GPCR—KRAS—skin cancer	1.27e-05	0.000128	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—BRAF—skin cancer	1.26e-05	0.000127	CbGpPWpGaD
Asenapine—HTR1E—Signaling Pathways—IL6—skin cancer	1.25e-05	0.000126	CbGpPWpGaD
Asenapine—DRD1—Signaling by GPCR—IL6—skin cancer	1.24e-05	0.000125	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—BRAF—skin cancer	1.24e-05	0.000125	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—BRAF—skin cancer	1.24e-05	0.000125	CbGpPWpGaD
Asenapine—DRD3—Signaling by GPCR—IL6—skin cancer	1.23e-05	0.000124	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—NRAS—skin cancer	1.22e-05	0.000123	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—NRAS—skin cancer	1.22e-05	0.000123	CbGpPWpGaD
Asenapine—HRH2—Signaling Pathways—TP53—skin cancer	1.22e-05	0.000123	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—BRAF—skin cancer	1.21e-05	0.000122	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—NRAS—skin cancer	1.21e-05	0.000122	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—NRAS—skin cancer	1.2e-05	0.000121	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—ERCC2—skin cancer	1.18e-05	0.000119	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—NRAS—skin cancer	1.18e-05	0.000119	CbGpPWpGaD
Asenapine—ADRB1—Signaling by GPCR—HRAS—skin cancer	1.17e-05	0.000118	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—NRAS—skin cancer	1.17e-05	0.000117	CbGpPWpGaD
Asenapine—HRH2—Signaling Pathways—HRAS—skin cancer	1.16e-05	0.000117	CbGpPWpGaD
Asenapine—ADRA2B—Signaling by GPCR—HRAS—skin cancer	1.16e-05	0.000117	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—KRAS—skin cancer	1.15e-05	0.000116	CbGpPWpGaD
Asenapine—ADRB2—Signaling by GPCR—HRAS—skin cancer	1.14e-05	0.000115	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—KRAS—skin cancer	1.14e-05	0.000114	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—KRAS—skin cancer	1.13e-05	0.000114	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—BRAF—skin cancer	1.13e-05	0.000114	CbGpPWpGaD
Asenapine—ADRB1—Signaling by GPCR—IL6—skin cancer	1.12e-05	0.000113	CbGpPWpGaD
Asenapine—HTR1A—Signaling by GPCR—HRAS—skin cancer	1.12e-05	0.000113	CbGpPWpGaD
Asenapine—HRH2—Signaling Pathways—IL6—skin cancer	1.11e-05	0.000112	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—NRAS—skin cancer	1.11e-05	0.000112	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—KRAS—skin cancer	1.11e-05	0.000112	CbGpPWpGaD
Asenapine—HTR2C—Signaling by GPCR—HRAS—skin cancer	1.11e-05	0.000112	CbGpPWpGaD
Asenapine—ADRA2B—Signaling by GPCR—IL6—skin cancer	1.11e-05	0.000112	CbGpPWpGaD
Asenapine—ADRB2—Signaling by GPCR—IL6—skin cancer	1.09e-05	0.00011	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—PTGS2—skin cancer	1.09e-05	0.00011	CbGpPWpGaD
Asenapine—ADRA2C—Signaling by GPCR—HRAS—skin cancer	1.08e-05	0.000109	CbGpPWpGaD
Asenapine—HTR1A—Signaling by GPCR—IL6—skin cancer	1.07e-05	0.000108	CbGpPWpGaD
Asenapine—HTR2C—Signaling by GPCR—IL6—skin cancer	1.06e-05	0.000107	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—NRAS—skin cancer	1.05e-05	0.000106	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—KRAS—skin cancer	1.05e-05	0.000106	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—KRAS—skin cancer	1.05e-05	0.000106	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—KRAS—skin cancer	1.04e-05	0.000105	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—NRAS—skin cancer	1.03e-05	0.000104	CbGpPWpGaD
Asenapine—ADRA2C—Signaling by GPCR—IL6—skin cancer	1.03e-05	0.000104	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—KRAS—skin cancer	1.03e-05	0.000104	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—KRAS—skin cancer	1.02e-05	0.000103	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—ERCC2—skin cancer	1e-05	0.000101	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—KRAS—skin cancer	1e-05	0.000101	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—HRAS—skin cancer	9.81e-06	9.89e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—HRAS—skin cancer	9.65e-06	9.73e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—HRAS—skin cancer	9.63e-06	9.71e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—KRAS—skin cancer	9.57e-06	9.65e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—HRAS—skin cancer	9.45e-06	9.53e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—NRAS—skin cancer	9.43e-06	9.51e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—IL6—skin cancer	9.39e-06	9.46e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—NRAS—skin cancer	9.34e-06	9.42e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—TP53—skin cancer	9.32e-06	9.4e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—TP53—skin cancer	9.31e-06	9.39e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—TP53—skin cancer	9.25e-06	9.33e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—IL6—skin cancer	9.24e-06	9.31e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—NRAS—skin cancer	9.22e-06	9.3e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—IL6—skin cancer	9.22e-06	9.29e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—TP53—skin cancer	9.06e-06	9.13e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—IL6—skin cancer	9.04e-06	9.12e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—KRAS—skin cancer	9.03e-06	9.1e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—NRAS—skin cancer	9.02e-06	9.09e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—NRAS—skin cancer	8.97e-06	9.05e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—HRAS—skin cancer	8.91e-06	8.99e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—TP53—skin cancer	8.91e-06	8.99e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—KRAS—skin cancer	8.91e-06	8.98e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—HRAS—skin cancer	8.9e-06	8.98e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—HRAS—skin cancer	8.85e-06	8.92e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—HRAS—skin cancer	8.78e-06	8.85e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—NRAS—skin cancer	8.73e-06	8.8e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—HRAS—skin cancer	8.66e-06	8.73e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—IL6—skin cancer	8.53e-06	8.6e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—HRAS—skin cancer	8.52e-06	8.59e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—IL6—skin cancer	8.52e-06	8.59e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—TP53—skin cancer	8.51e-06	8.58e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—IL6—skin cancer	8.47e-06	8.54e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—IL6—skin cancer	8.4e-06	8.47e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—IL6—skin cancer	8.29e-06	8.36e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—IL6—skin cancer	8.16e-06	8.23e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—HRAS—skin cancer	8.14e-06	8.2e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—KRAS—skin cancer	8.12e-06	8.18e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—KRAS—skin cancer	8.04e-06	8.11e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—TP53—skin cancer	8.02e-06	8.09e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—KRAS—skin cancer	7.94e-06	8e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—NRAS—skin cancer	7.92e-06	7.98e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—TP53—skin cancer	7.92e-06	7.98e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—NRAS—skin cancer	7.79e-06	7.86e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—IL6—skin cancer	7.79e-06	7.85e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—NRAS—skin cancer	7.77e-06	7.84e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—KRAS—skin cancer	7.76e-06	7.83e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—ERCC2—skin cancer	7.74e-06	7.81e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—KRAS—skin cancer	7.72e-06	7.79e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—HRAS—skin cancer	7.67e-06	7.74e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—NRAS—skin cancer	7.63e-06	7.69e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—HRAS—skin cancer	7.57e-06	7.63e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—KRAS—skin cancer	7.51e-06	7.57e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—IL6—skin cancer	7.34e-06	7.41e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—IL6—skin cancer	7.25e-06	7.31e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—TP53—skin cancer	7.21e-06	7.27e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—TP53—skin cancer	7.15e-06	7.21e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PTGS2—skin cancer	7.1e-06	7.16e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—NRAS—skin cancer	7.09e-06	7.15e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—TP53—skin cancer	7.06e-06	7.11e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—TP53—skin cancer	6.9e-06	6.96e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—HRAS—skin cancer	6.9e-06	6.96e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—TP53—skin cancer	6.86e-06	6.92e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—HRAS—skin cancer	6.83e-06	6.89e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—KRAS—skin cancer	6.82e-06	6.87e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—HRAS—skin cancer	6.75e-06	6.8e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—KRAS—skin cancer	6.71e-06	6.76e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—KRAS—skin cancer	6.69e-06	6.75e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—TP53—skin cancer	6.68e-06	6.73e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—IL6—skin cancer	6.6e-06	6.66e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—HRAS—skin cancer	6.6e-06	6.65e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—KRAS—skin cancer	6.57e-06	6.62e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—HRAS—skin cancer	6.56e-06	6.62e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—IL6—skin cancer	6.54e-06	6.6e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—IL6—skin cancer	6.46e-06	6.51e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—HRAS—skin cancer	6.38e-06	6.44e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—IL6—skin cancer	6.32e-06	6.37e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—IL6—skin cancer	6.28e-06	6.33e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—IL6—skin cancer	6.11e-06	6.16e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—KRAS—skin cancer	6.1e-06	6.15e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—TP53—skin cancer	6.06e-06	6.11e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PTGS2—skin cancer	6.01e-06	6.06e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—TP53—skin cancer	5.96e-06	6.01e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—TP53—skin cancer	5.95e-06	6e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—TP53—skin cancer	5.84e-06	5.88e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—HRAS—skin cancer	5.79e-06	5.84e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—HRAS—skin cancer	5.7e-06	5.75e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—HRAS—skin cancer	5.69e-06	5.74e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—HRAS—skin cancer	5.58e-06	5.63e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—IL6—skin cancer	5.54e-06	5.59e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—IL6—skin cancer	5.46e-06	5.5e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—IL6—skin cancer	5.44e-06	5.49e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—TP53—skin cancer	5.42e-06	5.47e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—IL6—skin cancer	5.34e-06	5.39e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—HRAS—skin cancer	5.19e-06	5.23e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—IL6—skin cancer	4.96e-06	5e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PTGS2—skin cancer	4.64e-06	4.68e-05	CbGpPWpGaD
